Cancer-related costs should be allocated in a comparable way—benchmarking costs of cancer in Nordic countries 2012–2017

Abstract

Background

High costs of cancer, and especially the increase in treatment costs, have raised concerns about the financial sustainability of publicly funded health care systems around the world. As cancers get more prevalent with age, treatment costs are expected to keep rising with aging populations. The objective of the study is to analyze the changes in cost of cancer care broken down into separate cost components and outcomes of cancer treatment in the Nordic countries 2012–2017.

Materials and methods

We estimated direct costs of cancer based on retrospective data from national registers: outpatient care and inpatient care in primary care and specialized care as well as medicine costs. The number of cancer cases and survival data was obtained from NORDCAN. Cancer was defined as ICD-10 codes C00–C97.

Results

Healthcare costs of cancer in real terms increased in all countries: CAGR was between 1 and 6% depending on the country. Medicine costs have increased rapidly (37–125%) in all countries during the observation period. In Finland and Denmark, inpatient care costs have decreased, whereas in Iceland, Norway, and Sweden, they have increased, although the number of inpatient days has decreased everywhere. The age-standardized cancer mortality has decreased constantly over time.

Conclusion

Cancer care in Nordic countries has significant differences in both cost structures and in the development of cost drivers, indicating differences in the organization of care and different focus in health policy. It is important to compare the cancer care costs internationally on a detailed level to understand the reasons for cost development. The registration of cost data, especially medicine costs, should be more standardized to enable better cost and outcomes comparisons between countries in the future.

Keywords:

• Cancer
• costs
• Nordic countries
• benchmarking
• cost trends

Acknowledgements

Ira Haavisto, Milja Asikainen, Bolette Danckert, and Elizabeth Johansson helped with data collection.

Disclosure statement

No potential conflict of interest was reported by the authors.

Data availability statement

The data are available upon request from the corresponding author

Additional information

Funding

This work was funded by the Nordic Cancer Union.